title: Glucose disturbances in non-diabetic patients receiving acute treatment with methylprednisolone pulses.
abstract: OBJECTIVE
  Methylprednisolone pulses are used in a variety of disease conditions, both for acute and chronic therapy. Although well tolerated, they increase glucose levels in both non-diabetic and diabetic patients. They may also be considered a significant risk for acute metabolic alterations. The purpose of this report is to determine the metabolic changes in blood glucose levels in non-diabetic patients receiving methylprednisolone pulses and identify the presence of predictive factors for its development.
  
  
  METHODS
  Observational, prospective study in 50 non-diabetic patients receiving 1 g intravenous methylprednisolone pulses for three consecutive days as an indication for diverse autoimmune disorders. Demographic, anthropometric, and metabolic variables were analyzed, and glucose, insulin and C-peptide levels after each steroid pulse were identified. Different variables and the magnitude of hyperglycemia were analyzed using Pearson's correlation.
  
  
  RESULTS
  50 patients were included, predominantly women (66%, n = 33). The average age was 41 ± 14 years with a BMI of 26 ± 3 kg/m². Baseline glucose was 83 ± 10 mg/dL. After each steroid pulse, glucose increased to 140 ± 28, 160 ± 38 and 183 ± 44, respectively (p < 0.001). C-peptide and insulin concentrations increased significantly (p < 0.001). The prevalence of fasting hyperglycemia after each pulse was 68%, 94% and 98%, respectively. We found no correlation between the magnitude of hyperglycemia and the studied variables.
  
  
  CONCLUSIONS
  Methylprednisolone pulses produced significant increases in fasting glucose in most patients without diabetes. Further studies are needed to define its role in long-term consequences.
authors.affiliation: Endocrinology Service, Subdivision of Investigation, College of Medicine, Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico. 　hectoreloytamez@aol.com
authors.forename: Hector Eloy
authors.initials: HE
authors.lastname: Tamez Perez
authors.forename: María Dolores
authors.initials: MD
authors.lastname: Gómez de Ossio
authors.forename: Dania Lizet
authors.initials: DL
authors.lastname: Quintanilla Flores
authors.forename: Mayra Ivonne
authors.initials: MI
authors.lastname: Hernández Coria
authors.forename: Alejandra Lorena
authors.initials: AL
authors.lastname: Tamez Peña
authors.forename: Gissén Jazmín
authors.initials: GJ
authors.lastname: Cuz Pérez
authors.forename: Stephanie Lissette
authors.initials: SL
authors.lastname: Proskauer Peña
mesh_terms: D000293:Adolescent; D000328:Adult; D001786:Blood Glucose / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects*; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced* / Q000378:metabolism; D008297:Male; D008775:Methylprednisolone / Q000009:adverse effects*; D008800:Mexico; D011446:Prospective Studies; D020551:Pulse Therapy, Drug; D012307:Risk Factors
chemical_list: D001786:Blood Glucose; D005938:Glucocorticoids; D008775:Methylprednisolone